YU60198A - Supstituisani derivati indazola i njihova upotreba kao fosfodiesteraze (pde) tipa iv i inhibitora faktora nekroze tumora (tnf) - Google Patents

Supstituisani derivati indazola i njihova upotreba kao fosfodiesteraze (pde) tipa iv i inhibitora faktora nekroze tumora (tnf)

Info

Publication number
YU60198A
YU60198A YU60198A YU60198A YU60198A YU 60198 A YU60198 A YU 60198A YU 60198 A YU60198 A YU 60198A YU 60198 A YU60198 A YU 60198A YU 60198 A YU60198 A YU 60198A
Authority
YU
Yugoslavia
Prior art keywords
pde
tnf
type
necrosis factor
tumor necrosis
Prior art date
Application number
YU60198A
Other languages
English (en)
Inventor
Anthony Marfat
Original Assignee
PFIZER INC., proizvodno i trgovinsko preduzeće organizovano po propisima države Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER INC., proizvodno i trgovinsko preduzeće organizovano po propisima države Delaware filed Critical PFIZER INC., proizvodno i trgovinsko preduzeće organizovano po propisima države Delaware
Publication of YU60198A publication Critical patent/YU60198A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ovaj pronalazak se odnosi na formulu (I) i njene farmaceutski prihvatljive soli gde su R, R1 i R2 kao što je definisano, ovaj pronalazak se dalje odnosi na farmaceutske smeše koje sadrže i postupke za uzpotrebu jedinjenja formule (I) ili njene farmaceutski prihvatljive soli za inhibiciju fosfodiasteraeze (PDE) tipa IV ili javljanja faktora nekroze tumora (TNF) kod sisara.
YU60198A 1996-06-25 1998-12-24 Supstituisani derivati indazola i njihova upotreba kao fosfodiesteraze (pde) tipa iv i inhibitora faktora nekroze tumora (tnf) YU60198A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2038596P 1996-06-25 1996-06-25

Publications (1)

Publication Number Publication Date
YU60198A true YU60198A (sh) 1999-09-27

Family

ID=21798354

Family Applications (1)

Application Number Title Priority Date Filing Date
YU60198A YU60198A (sh) 1996-06-25 1998-12-24 Supstituisani derivati indazola i njihova upotreba kao fosfodiesteraze (pde) tipa iv i inhibitora faktora nekroze tumora (tnf)

Country Status (43)

Country Link
US (1) US6040329A (sh)
EP (1) EP0912558B1 (sh)
JP (1) JP3152940B2 (sh)
KR (1) KR20000022516A (sh)
CN (1) CN1080260C (sh)
AP (1) AP1025A (sh)
AR (1) AR007456A1 (sh)
AT (1) ATE244713T1 (sh)
AU (1) AU716376B2 (sh)
BG (1) BG64052B1 (sh)
BR (1) BR9712782A (sh)
CA (1) CA2258285C (sh)
CO (1) CO4900056A1 (sh)
CZ (1) CZ423398A3 (sh)
DE (1) DE69723447T2 (sh)
DK (1) DK0912558T3 (sh)
DZ (1) DZ2254A1 (sh)
EA (1) EA002274B1 (sh)
ES (1) ES2201299T3 (sh)
GT (1) GT199700075A (sh)
HK (1) HK1018700A1 (sh)
HN (1) HN1997000079A (sh)
HR (1) HRP970350B1 (sh)
HU (1) HUP9903009A3 (sh)
ID (1) ID18579A (sh)
IL (1) IL127036A (sh)
IS (1) IS4910A (sh)
MA (1) MA24225A1 (sh)
MY (1) MY116915A (sh)
NO (1) NO986103L (sh)
NZ (1) NZ332752A (sh)
OA (1) OA10934A (sh)
PA (1) PA8432301A1 (sh)
PL (1) PL330974A1 (sh)
PT (1) PT912558E (sh)
SI (1) SI0912558T1 (sh)
SK (1) SK176598A3 (sh)
TN (1) TNSN97108A1 (sh)
TR (1) TR199802685T2 (sh)
TW (1) TW434237B (sh)
WO (1) WO1997049702A1 (sh)
YU (1) YU60198A (sh)
ZA (1) ZA975581B (sh)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3102697A (en) 1996-06-19 1998-01-07 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
KR100338610B1 (ko) * 1996-09-04 2002-05-27 디. 제이. 우드, 스피겔 알렌 제이 인다졸 유도체 및 포스포디에스터라제 (pde) 유형 iv 및 종양괴사인자 (tnf) 생산의 억제제로서 그의 용도
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
YU25400A (sh) * 1997-11-04 2003-07-07 Pfizer Products Inc. Terapeutski aktivna jedinjenja sa indazolom
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
ES2239063T3 (es) * 1999-12-23 2005-09-16 Icos Corporation Inhibidores de la fosfodiesterasa ciclica especifica de amp.
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
US7153871B2 (en) 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
CN1300116C (zh) * 2001-04-16 2007-02-14 卫材株式会社 1h－吲唑化合物
EA011213B1 (ru) 2001-12-14 2009-02-27 Лаборатуар Сероно Са Способ индуцирования овуляции с использованием ингибитора изоформы фосфодиэстеразы 4 (pde4)
EP1539697A1 (en) 2002-07-19 2005-06-15 Memory Pharmaceutical Corporation Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
AU2003256601B2 (en) 2002-07-19 2009-10-29 Memory Pharmaceuticals Corporation 6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
US7087625B2 (en) 2002-11-19 2006-08-08 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
SG168409A1 (en) * 2003-04-18 2011-02-28 Memory Pharm Corp Pyrazole derivatives as phosphodiesterase 4 inhibitors
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
CN101166733A (zh) 2004-10-15 2008-04-23 记忆药物公司 作为磷酸二酯酶4抑制剂的吡唑衍生物
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
EP1891060A2 (en) * 2005-05-30 2008-02-27 Ranbaxy Laboratories Limited 3-indazolyl-isoxazoline derivatives as inhibitors of phosphodiesterase type-iv
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7781460B2 (en) 2005-09-05 2010-08-24 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-IV
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN103497185A (zh) 2007-03-14 2014-01-08 兰贝克赛实验室有限公司 用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2651296T3 (es) * 2009-10-30 2018-01-25 Janssen Pharmaceutica, N.V. Derivados de imidazo[1,2-b]piridacina y su uso como inhibidores de PDE10
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
EP3137454A1 (en) 2014-04-28 2017-03-08 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
KR20220167441A (ko) * 2021-06-11 2022-12-21 주식회사 메타센테라퓨틱스 신규한 인돌 유도체 및 이의 최종당화산물 관련 질환의 치료 용도
KR20220167804A (ko) * 2021-06-11 2022-12-22 주식회사 메타센테라퓨틱스 인돌 유도체를 포함하는 최종당화산물 관련 질환의 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB753573A (en) * 1953-06-17 1956-07-25 Ici Ltd New dyestuffs intermediates
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
TW223004B (sh) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
WO1993019749A1 (en) * 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
JPH07215952A (ja) * 1993-12-06 1995-08-15 Otsuka Pharmaceut Factory Inc カテコール誘導体
NZ292991A (en) * 1994-10-20 1999-02-25 Pfizer Bicyclic tetrahydropyrazolopyridines that are selective inhibitors of phosphodiesterase (pde) type iv or the production of tnf and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
ZA975581B (en) 1998-12-24
ID18579A (id) 1998-04-23
HUP9903009A2 (hu) 2000-05-28
MA24225A1 (fr) 1997-12-31
EP0912558B1 (en) 2003-07-09
KR20000022516A (ko) 2000-04-25
NO986103D0 (no) 1998-12-23
EA002274B1 (ru) 2002-02-28
SI0912558T1 (en) 2003-10-31
SK176598A3 (en) 2000-06-12
CA2258285C (en) 2002-11-26
CN1080260C (zh) 2002-03-06
IL127036A0 (en) 1999-09-22
TW434237B (en) 2001-05-16
EP0912558A1 (en) 1999-05-06
GT199700075A (es) 1998-12-04
PT912558E (pt) 2003-11-28
AU2785797A (en) 1998-01-14
OA10934A (en) 2002-02-18
PL330974A1 (en) 1999-06-21
US6040329A (en) 2000-03-21
ES2201299T3 (es) 2004-03-16
DE69723447D1 (de) 2003-08-14
CO4900056A1 (es) 2000-03-27
AP9701020A0 (en) 1997-07-31
DZ2254A1 (fr) 2002-12-18
PA8432301A1 (es) 1999-12-27
AR007456A1 (es) 1999-10-27
AP1025A (en) 2001-11-19
BR9712782A (pt) 1999-12-07
JPH11514668A (ja) 1999-12-14
HK1018700A1 (en) 1999-12-30
NO986103L (no) 1998-12-23
IL127036A (en) 2001-06-14
EA199801047A1 (ru) 1999-06-24
HRP970350A2 (en) 1998-06-30
TR199802685T2 (xx) 1999-03-22
CZ423398A3 (cs) 1999-12-15
WO1997049702A1 (en) 1997-12-31
HN1997000079A (es) 1997-12-26
DK0912558T3 (da) 2003-08-18
HUP9903009A3 (en) 2002-01-28
CA2258285A1 (en) 1997-12-31
JP3152940B2 (ja) 2001-04-03
CN1223651A (zh) 1999-07-21
HRP970350B1 (en) 2003-04-30
DE69723447T2 (de) 2003-12-24
IS4910A (is) 1998-11-27
NZ332752A (en) 2001-04-27
AU716376B2 (en) 2000-02-24
MY116915A (en) 2004-04-30
BG103056A (en) 1999-10-29
BG64052B1 (bg) 2003-11-28
TNSN97108A1 (fr) 2005-03-15
ATE244713T1 (de) 2003-07-15

Similar Documents

Publication Publication Date Title
YU60198A (sh) Supstituisani derivati indazola i njihova upotreba kao fosfodiesteraze (pde) tipa iv i inhibitora faktora nekroze tumora (tnf)
YU16397A (sh) Supstituisani derivati indazola i srodna jedinjenja
BG103195A (en) Substituted indazole derivatives and their application as inhibitors of phosphodiesterase (pde) type iv and of the production of a tumournecrotic factor (tnf)
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
BG103964A (en) SUBSTITUTED PYRAZOLS AS p38 KINASE INHIBITORS
NO2015020I2 (no) Ceritinib eller et farmasøytisk akseptabelt salt derav
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
ATE18765T1 (de) Pharmazeutische zusammenstellungen.
DE69705829D1 (de) Meta-substituierte phenylsulphonamidderivate
ES2185307T3 (es) Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion.
EP0353955A3 (en) Novel compounds
EA200501104A1 (ru) Производные пиридина, пригодные для ингибирования системы обмена натрия/кальция
NO983444L (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
DK0758312T3 (da) Substituerede fusionerede og broforbundne bicykliske forbindelser som terapeutiske midler
DK0635012T3 (da) Bis-aryl-carbinolderivater uden broer, præparater indeholdende disse og fremgangsmåder til anvendelse af disse
ES543784A0 (es) Procedimiento de preparacion de un derivado 1,1-difenilpro- pan-1-ol